Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.75 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.59 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2123014 | 0.96 | S1PR1 (0.81) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL2124223 | 0.92 | S1PR1 (0.63) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL13019822 | 0.90 | S1PR1 (0.69) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL2124526 | 0.90 | S1PR1 (0.83) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL401724 | 0.90 | S1PR1 (0.92) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL2124883 | 0.88 | S1PR1 (0.67) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL403211 | 0.85 | S1PR1 (1.00) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL2125935 | 0.85 | S1PR1 (0.75) | S1PR1S1PR3S1PR5 | |
| SCHEMBL1968502 | 0.85 | S1PR1 (0.81) | S1PR1S1PR3CYP2C9 | |
| SCHEMBL401604 | 0.84 | S1PR1 (0.92) | S1PR1S1PR3S1PR5CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443115-B1 | Pyrrolo-pyridine derivatives useful to treat diseases connected to S1P1 receptors | GLAXO GROUP LTD (GB) | 2013-08-28 | — | — | EP | claimed |
| US-20120101123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | claimed |
| EP-2443115-B1 | Pyrrolo-pyridine derivatives useful to treat diseases connected to S1P1 receptors | GLAXO GROUP LTD (GB) | 2013-08-28 | — | — | EP | disclosed |
| EP-2443115-B1 | Pyrrolo-pyridine derivatives useful to treat diseases connected to S1P1 receptors | GLAXO GROUP LTD (GB) | 2013-08-28 | — | — | EP | disclosed |
| US-20120101123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| WO-2010145201-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101123-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | S1PR1 1075/4885S1PR3 1079/4885S1PR5 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.